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Abstract: The decreased bone mineral density and compromised bone strength predispose 
individuals to skeletal osteoporosis. Both prostate cancer and bone metastasis caused by cancer 
invasion have remained a great challenge to researchers. With the advancement in the fields of 
biochemistry and biomechanics, the molecular mechanisms that make prostate cancer metas-
tasize to bone have recently been identified, and they provide new molecular targets for drug 
development. Many biochemical by-products have been identified to help in understanding the 
interaction between the bone and the tumor. Enhanced clinical management of patients with 
bone metastases was reported during the past decade; however, the anticipated risk and the 
response to the therapy are still challenging to assess. In this review, the key players that play 
a dominant role in secondary osteoporosis are addressed. An attempt is made to provide the 
readers with a clear understanding of the communication pathways between each of the cell 
types involved in this vicious cycle. Furthermore, the role of Wnts, sclerostin, RANKL, PTHrP, 
and their respective clinical studies are addressed in this study.
Keywords: prostate cancer metastatic bone disease (PCa MBD), vicious cycle, macrophages, 
Wnts signaling
Introduction
As per 2016 statistics, the mortality rate associated with prostate cancer (PCa) stands 
fifth globally. Reports of surveillance research program of the National Institutes of 
Health unveiled that PCa is affecting male global population strongly. Accordingly, out 
of every 100,000 men, 124.9 new cases are registered, while 20.7 patients die annually. 
On the basis of 2011–2013 data, 12.9% male population has a PCa morbidity risk at 
any stage of life. In metastases, the final phase of PCa, neoplasmic cells proliferate 
in bones and cause fatal osteolytic and osteoblastic abrasions. Consequently, 90% of 
advanced-stage PCa patients have very low survival rate and they are more prone to 
complications such as skeletal fractures, intolerable bone pain, together with spinal cord 
compression. Unfortunately, 15%–35% of the patients develop metastases initiated by 
transition of primary PCa cells to mesenchymal entity. Modified cells disseminate from 
the primary source, attain bone-like morphology, and enter and multiply rapidly in the 
bone tissue causing bone fractures. However, the mechanism by which the PCa cells 
amend bone microenvironment to facilitate their survival and growth is ambiguous.
During the past decade, new therapeutic strategies have emerged to understand 
and cure bone metastasis in PCa.1 Homotypic interaction among cancerous cells in 
conjunction with heterotypic interaction among neoplasm cells, osteoclasts, and osteo-
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blasts plays an important role in determining the course and 
complications of metastatic bone disease (MBD). Osteolysis 
releases many growth factors such as transforming growth 
factor (TGF), insulin-like growth factors (IGFs), and fibro-
blast growth factors (FGFs) into the tumor microenvironment 
that facilitate bone matrix remodeling. Consequently, the 
vicious cycle of metastasis is continuous by stimulating the 
growth of neoplasmic cells together with the growth factor-
mediated phenotypic changes in cancerous cells. Bone loss 
from osteoclastic bone degradation is characteristic of solid 
tumor cells’ secondary metastases. This situation is further 
complicated in PCa due to inappropriate bone formation. 
Potential chemotherapeutic targets to restrain neoplasmic 
growth and subsequent bone metastasis include physical fac-
tors within the bone microenvironment, such as acidic pH, 
little oxygen, and high extracellular calcium levels.
In this article, keeping in view the need to explore the 
unrevealed biochemical mechanisms of PCa MBD, we 
address the key players of the vicious cycle, their com-
munication pathways, and the preclinical/clinical trials and 
strategies to manipulate the role of such players, to minimize 
and/or reverse the predominant osteoblastic response and to 
halt the osteolytic activity.
Osteoblastic and osteolytic bone 
metastasis
Bone remodeling is a continuous mechanism through which 
the skeleton endures all over the life. Bone resorption and 
bone formation are two processes which occur in coupling 
during bone remodeling. Such a practice of bone proves it 
is a dynamic organ. A disparity among these processes gives 
rise to various bone diseases, including osteoporosis, arthri-
tis, osteophytes (bone spur), osteolysis (bone degradation), 
craniosynostosis, knee effusion, and osteochondroma. The 
process of bone remodeling is based on a complex network 
comprising various growth factors and signaling pathways. 
The bone-resorbing cells (osteoclasts) and bone-forming cells 
(osteoblasts) are the key factors of targeted bone remodeling. 
Mesenchymal stem cells which are abundant in nature dif-
ferentiate into preosteoblasts. Likewise, osteoclast progeni-
tor cells differentiate into osteoclast precursors. A number 
of autocrine and paracrine factors are involved in such cell 
differentiation.2 The bone-forming connective tissue cells, 
named as active osteoblasts, originate at the surface of the 
bone from preosteoblasts. These cells fuse and do not cleave, 
and their main function includes the emission of the collagen 
matrix and calcium salts. Calcification of the extravasated 
matrix surrounding the osteoblastic cells traps the cells 
within it, due to which the cell changes its structure and 
is transformed into osteocyte; these osteocytes participate 
actively as bone-forming cells. The activity of the osteocytes 
and the substance they secrete are themselves influenced by 
a variety of factors including the mechanical stress on the 
bone, hormones, and calcium and phosphorous concentra-
tions in the bloodstream.
Multifarious communication pathways among the osteo-
clast and osteoblast progenitors, at several phases of dif-
ferentiation, participate in the bone remodeling cycle. Bone 
lining cells including the osteocytes, osteoblast progenitors, 
and osteoblast precursors monitor their own functioning 
along with the instigation of osteoclast synthesis, attach-
ment, execution, and decay. In response, the osteoclasts 
govern the level of osteoblast functioning by releasing the 
factors (inside the milieu and membrane). Such a complex 
network consisting of various signaling pathways of inter-
cellular interactions makes the bone capable to respond 
appropriately to hormonal, mechanical, and inflammatory 
stimuli to present a strong and versatile composition for 
human function.
Triphasic bone remodeling
In a healthy bone, remodeling may be described as the pro-
cess where old or damaged tissue is resorbed by osteoclasts 
and the resorbed lacunae are filled to the original level by 
osteoblasts. The process is divided into three major phases: 
initiation, transition, and termination. These phases are 
depicted in Figure 1.
At the initial stage of bone resorption, the mature osteo-
clast sticks tightly to the bone by creating a specialized 
Figure 1 Overview of the bone dynamics.
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isolated compartment. The membrane adjoining this part of 
the bone (ruffled membrane) contains proteins that acidify 
the compartment nearby the bone. The acid firstly liquefies 
the minerals in the bone, and then the digestive enzymes 
break down type I collagen and other proteins. Expiring of 
osteoclasts due to apoptosis ends up this procedure of bone 
resorption. The direction of major communication is opposite 
between the initiation and transition phases: from osteoblasts 
to osteoclast precursors in initiation, and from osteoclasts to 
osteoblast precursors (or bidirectionally) in transition. The 
initiation phase includes stimulation of osteoclast formation 
due to RANKL, which also directs the osteoclasts toward the 
sites of macrodamage. Duration of osteoclastic bone resorp-
tion is almost 21 days in human bone. Once the osteoclasts 
have removed the old tissue, they move forward and undergo 
apoptosis and the transition phase starts. This phase includes 
the recruitment and differentiation of osteoblasts and the 
grounding of resorbed surface for bone formation.3
The termination phase eventually mineralizes and forms 
osteoid (new bone), and the process of mass-neutral bone 
renewal is complete. The termination phase takes a longer 
period as compared to the initiation phase. Osteoprotegerin 
(OPG) is associated with the initial phase, in which it 
counteracts RANKL osteoclastogenic activity, but there are 
evidences which assure a possible role of OPG in the termi-
nation phase as well. OPG may, indeed, protect the osteoid 
from osteoclastic resorptive activity during bone formation. 
In Figure 1, the formation and resorption are presented. Bone 
mass and bone quality both are affected by osteoclast–osteo-
blast communications. Excessive remodeling decreases the 
bone mass, whereas restrained bone remodeling increases it. 
Suppressed bone remodeling reduces the bone quality due to 
accumulation of microfractures and reduced reformation of 
bone architecture.4 Deep understanding of osteoclast–osteo-
blast communication during bone remodeling is a prerequisite 
for designing interventions to avoid bone loss while retaining 
bone quality and for treating diseases such as osteoporosis, 
breast cancer and PCa, bone metastasis, and fracture repair.
Vicious cycle and its mechanics
PCa cells release factors responsible for bone remodeling. 
A schematic of the vicious cycle is presented in Figure 2. 
A number of factors contributing to bone remodeling are 
secreted by PCa cells. These numerous factors include the 
bone morphogenetic proteins (BMPs; they are multifunc-
tional growth factors that belong to the TGF-β superfam-
ily), TGF-β, (PTHrP: this is a protein secreted by the cancer 
cells and acts as an endocrine, autocrine, paracrine, and 
intracrine hormone), adrenomedullin, OPG, RANK, and 
RANKL. This process is called osteomimicry. Osteoclast 
differentiation into more mature stages gets faster because 
of these secreted factors. Such an effect occurs directly or 
indirectly through osteoblastic cells. In turn, during bone 
resorption, the osteoclasts secrete a number of growth fac-
tors that are accumulated in the impregnated bone milieu 
and proficient to stimulate tumor development. The factors 
involved in the vicious cycle are remarkably diverse and are 
responsible for the histologic and phenotypic heterogeneity 
of bone metastases patients. PCa patients have a high affinity 
to encounter osteoblastic bone metastasis. This phenotype is 
found to be the most prevailing malady at present and the 
main reason for cancer patients’ fatality and infirmity. The 
vicious cycle is shown in Figure 2. The means regulating 
the intensification of this phenotype are not well identified 
yet. Generally, the characteristic response linked with PCa 
bone metastasis is found to be osteoblastic, but there are 
some adequate facts proving that osteolytic events are also 
in progress.5 A part of the osteolysis may be ascribed to 
androgen dearth, while the osteolytic features expressed by 
the PCa cells may take a part as well. Despite the instigat-
ing phenomena, osteolysis is extremely expected to result in 
extricate of persuasive growth factors from the bone matrix 
that positively affect the development of cancer cells. Several 
studies have been conducted to address this issue directly, 
in which the effects of osteolysis-hindering agents on PCa 
bone metastases have been analyzed. Such agents include 
the use of bisphosphonates to target the active osteoclasts 
Tumor
Cytokines and
growth factors
Osteoblasts
Osteoclasts
Growth factors
Metastasized
bone
RANKL
Figure 2 The schematic of vicious cycle.
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or exploiting the OPG/RANK/RANKL signaling pathway 
to hinder the differentiation of preosteoclasts.
Several studies are available in literature to demonstrate 
bone remodeling. Komarova and her research group6 dis-
cussed a model in which the key factors considered were 
the cell population dynamics of osteoclasts and osteoblasts. 
The chemical quantities were not elaborated as functions of 
time or location. However, the biochemical mechanisms were 
integrated in an abstract way. The inclusion of osteocytes, 
their biochemical processes, and their interactions with other 
bone remodeling cells in a mathematical model may play a 
vital role to give a significant advancement to this field. In 
2013, Graham et al7 developed an improved mathematical 
model for the biochemical systems in bone remodeling. The 
derivation of this model was motivated by the fact that in most 
of the clinical trials, explicit chemical data for this mechanism 
are not available. The model focused on the RANK/RANKL/
OPG pathway and its consequences. The actions of growth 
factors such as TGF-β and other cytokines on bone remodel-
ing cells were also incorporated in this model.
Sclerostin: an osteocyte-enhanced 
local regulator of bone remodeling
Osteocytes express growth factors that encourage bone 
formation. They secrete sclerostin, which is a cysteine-knot-
containing protein that inhibits bone formation and affects 
both osteoblast and osteoclast activity. Sclerostin inhibits 
the Wnt signaling pathway by binding to LRP5 coreceptor, 
ensuing mutations in gene encoding. Gkotzamanidou et al8 
summarized the function of sclerostin in bone metastases 
of cancer. They analyzed that in most of the cancers, high 
sclerostin levels are found in patients’ plasma and serum, 
whereas the situation is reverse in PCa. Low levels of scleros-
tin along with morphogenic protein-6 may be considered a 
biomarker of PCa metastatic progression. In breast cancer, 
in vitro data suggest that within the metastatic bone region, 
the osteoblastic activity is inhibited by high expression of 
sclerostin. On the basis of this observation, it was concluded 
that sclerostin might be involved in inhibition of bone forma-
tion in breast cancer and malignant neoplasm-related bone 
diseases.
Osteocytes not only secrete the growth factors that 
stimulate bone formation, but also secrete sclerostin which 
is a cysteine-knot-containing protein that inhibits bone for-
mation and affects both osteoblast and osteoclast activity. 
Sclerostin is a bone-specific molecule that binds LRP5, and 
thus prevents binding of Wnt proteins, leading to inhibition 
of the pathway loss-of-function mutations of gene encoding.
There are preclinical trials9 and clinical trials10 avail-
able in literature, emphasizing on the role of sclerostin in 
bone remodeling. In 2012, Yavropoulou et al11 performed 
a clinical trial to investigate the effect of serum sclerostin 
levels in Paget’s disease and PCa with bone metastases. A 
significant positive relationship between sclerostin levels and 
bone turnover markers in metastatic PCa was detected. They 
highlighted a number of factors that can stimulate sclerostin 
production. Cytokines produced by PCa cells could also 
contribute to the increased circulating levels of sclerostin 
observed in PCa metastasis to the skeleton. This increased 
sclerostin production may, in turn, stimulate RANKL and 
bone resorption. Sclerostin is encoded as SOST gene product 
that reduces osteoblastic bone formation by inhibiting canoni-
cal Wnt/β-catenin signaling (discussed in the “Wnts induced 
activities in PCa bone metastases” section). Sclerostin was 
recently shown to upregulate the expression of RANKL by 
osteocyte-like cells and promotes osteoclastogenesis,12 sup-
porting the view that osteocytes are targets for the action of 
sclerostin.
Later, in 2013, Larson et al10 performed for the first time a 
detailed analysis of bone remodeling proteins in human speci-
mens of PCa bone metastases. Based on the study findings, 
they acknowledged the findings in Yavropoulou et al11 and 
revealed that sclerostin was elevated in PCa bone metastases 
and was found to inhibit bone formation, promote osteoclast 
formation, and promote bone degradation. In studying the 
regulation of bone mass, the measurement of serum sclerostin 
level is a new approach and may serve as an effective tool in 
monitoring the efficiency of several therapies and detecting 
bone disorders. In multiple myeloma, sclerostin is produced 
by the myeloma cells, and is elevated in the serum or plasma 
of the patients and correlates with extensive bone disease and 
adverse myeloma features. Sclerostin expression is reduced 
in case of PCa, and in combination with BMP-6 and noggin 
expression, may work as prognostic predictor for metastatic 
progression. In case of breast cancer, in vitro data indicate 
that malignant cell induces the expression of sclerostin 
to inhibit osteoblasts in the metastatic bone area. In PCa 
patients, the role of sclerostin in bone metabolism as well as 
its relation with sex steroids is not explicitly known. In order 
to answer these mysteries, Garcia-Fontana et al13 conducted a 
cross-sectional study that included healthy controls and PCa 
patients. They gave a brief statistical analysis and concluded 
that the sclerostin levels were increased significantly in PCa 
patients, particularly in those who had androgen-deprivation 
therapy. They also concluded that there is an inverse relation 
between testosterone and sclerostin levels.
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Wnts induced activities in PCa bone 
metastases
The Wnt gene family was discovered in 1982 by Nusse and 
Varmus. Currently having 19 members, the Wnt proteins are 
a big family of cysteine-rich glycoproteins. They primarily 
work during development in order to control branching 
morphogenesis and body axis symmetry.14 Wnts exert their 
biological effect through three signaling pathways, which 
we can separate by their ability to stabilize catenin. Non-
canonical Wnts bind to a variety of receptors, including 
receptor tyrosine kinases, and mediate a lot of actions, some 
of which oppose canonical Wnt signaling. It has been proven 
that Wnt signaling plays some very important roles during 
organ and tissue homeostasis, bone biology, and embryonic 
development. The Wnt signaling pathways are defined as 
a group of signal transduction pathways which consist of 
proteins that pass signals into cell surface receptors. Wnt 
signaling also regulates bone mass with the help of multiple 
mechanisms such as proliferation, coupling to osteoclast 
function and osteoblast differentiation.15
Several proteins involved in Wnt signaling are involved in 
prostate tumor-induced osteoblastic activity,15 indicating that 
small-molecular targeting Wnt signaling may be an effective 
intervention for PCa metastasis. Very recently, Tseng et al16 
revealed through preclinical trials that caffeic acid phenethyl 
ester (CAPE), a main bioactive component extracted from 
honeybee hive propolis, suppresses migration and invasion 
of PCa cells via activation of non-canonical Wnt signaling. 
Therefore, CAPE treatment can prove to be a potential inter-
vention for PCa metastasis.
Studies are available in literature to investigate the 
contribution of the Wnt signaling pathway in PCa growth, 
incidence of bone metastases, and osteoblastic phenotype 
of bone metastases. Hall et al17 demonstrated elevated 
Dickkopf-1 (DKK-1, a secreted glycoprotein encoded by 
the DKK1 gene) expression as an early event in PCa and 
declined DKK-1 expression as a later event in progressed 
PCa (advanced bone metastases). The decline of DKK-1 
in bone metastases is interlinked with Wnts’ osteoblas-
tic activity and supports a model in which DKK-1 is a 
molecular switch that transitions the phenotype of PCa 
osseous lesions from osteolytic to osteoblastic. Thudi et al18 
adopted a strategy of overexpressing the Wnt antagonist, 
DKK-1, in the mixed osteoblastic and osteolytic Ace-1 PCa 
cells. They concluded that DKK-1 proved to be oncogenic 
and inhibited Wnt signaling and, thus, the bone formation 
(osteoinduction).
Wnt mRNAs are expressed in PCa cell lines and as 
compared with non-neoplastic prostate tissues, Wnt mRNA 
expression increases in primary PCa. In PCa bone metasta-
ses, Wnts induce osteoblastic activity, although it is not yet 
clear if Wnt mediates this activity due to a direct action on 
the osteoblasts or by activating some other pro-osteoblastic 
factors, for instance, BMP. Cancer models have confirmed 
that mutations or altered expression of components of Wnt 
pathways are strongly related with prostate tumors. Wnt path-
way and the downstream effector, catenin, play a vital role in 
the development and progression of PCa skeletal metastasis. 
Wnts influence tumor growth and survival (autocrine effects) 
and modulate bone cell growth as well as differentiation 
(paracrine effects). Canonical Wnts stimulate osteoblast min-
eralization and differentiation. In 2006, Hall et al15 identified 
that the Wnts produced by PCa induce osteoblastic activity 
in bone metastases and Wnt signaling could work both in 
paracrine and autocrine manner to help tumor cell growth and 
osteoblast differentiation. The preclinical and clinical studies 
to control the osteoblastic activities require much attention, 
especially to understand the pathways and the interference 
with endothelin-1 and BMPs.
In 2008, Robinson et al19 speculated on targeted studies 
of Wnt pathways for therapeutic treatment, and Dai et al20 
conducted clinical trials to explore Wnt-induced BMP 
mechanism. It was observed that PCa mediates pro-osteoblast 
activity through both canonical and non-canonical Wnts, 
which, in turn, contributes to osteoblast activity through 
BMP-dependent and BMP-independent pathways.
In 2009, Bisson and Prowse21 reported that Wnt signal-
ing regulates the differentiation and self-renewal of PCa 
cells with the characteristics of stem cells. Their studies 
revealed that treatment with Wnt inhibitors may reduce both 
self-renewal and prostasphere size, while addition of Wnt 3a 
caused increases self-renewal and the prostasphere size. Tai 
et al22 reported a new molecular therapeutic target in PCa 
bone metastasis and concluded that by downregulating miR 
126, osteoblast-derived, Wnt-induced secreted protein 1 
strengthens PCa. Various proteins involved in Wnt signaling 
have a role in prostate tumor-induced osteoblastic activity, 
which indicates that small-molecular targeting Wnt signaling 
might be an efficient intervention for PCa metastasis. Very 
recently, Tseng et al16 revealed through preclinical trials that 
via activation of non-canonical Wnt signaling, CAPE sup-
presses the migration and invasion of PCa cells. Therefore, 
CAPE treatment can prove to be a possible intervention for 
PCa metastasis.
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Klipp and Liebermeister23 meticulously reviewed the 
signaling pathways and discovered their hidden role in the 
stimulation and development of oncogenesis. It was revealed 
that the cross talk between ERK signaling proteins and Wnt 
pathway generates positive feedback oncogenic loop that 
promotes different types of neoplasms. They were able to dem-
onstrate the existent ERK/Wnt pathway cross talk mechanism 
via a persuasive model through amalgamation of the inclusive 
pathways’ mathematical models and experimental results. 
Based on the accepted assumption that mutations in signaling 
pathways are a conductive factor for cancer, it was found that 
mutations could activate both the pathways simultaneously 
resulting in permanent changes in the structure and function 
of both the pathways via cross talk-embedded feedback loop.
Role of PTH/PTHrP in bone 
metastasis
Besides structure, parathyroid hormone (PTH) and parathy-
roid hormone-related protein (PTHrP) share similarity in 
biological action and are important mediators of bone remod-
eling through osteoclastogenesis. Under normal physiological 
conditions, bone remodeling process consists of a series of 
highly coordinated and closely regulated steps. Together with 
regulating calcium concentration, both aforementioned pep-
tide mediators encourage osteolysis by binding to PTH-1R 
receptor on osteoblasts. The aftermath of this action is the 
upregulation of RANKL, coupled with the suppression of 
its decoy receptor, osteoprotegrin, by osteoblasts. RANKL 
activates preosteoclasts’ differentiation, migration, and fusion 
to form multinucleate mature osteoclasts to initiate bone 
resorption. Release of lysosomal enzymes such as cathepsin 
K by the osteoclasts results in irregular scalloped cavities, 
Haversian canals, on the bone surface. Afterward, the mac-
rophage cells replace the osteoclasts to degrade collagen, 
deposit proteoglycans for bone cement lining, and release 
growth factors to stimulate osteoblasts for the formation 
phase. Osteoblasts complete the bone remodeling cycle by 
filling the cavities along with deposition of mineralizable 
matrix. Clinical analysis of various tumors from breast, 
prostate, thyroid, lung, and kidney identified PTHrP as a 
neoplasm-derived humoral factor.24 Upregulation of PTHrP 
and PTH-1R receptor in tumor cells contributes to their sur-
vival, proliferation, and adhesion via intracrine, paracrine, 
and autocrine signaling, hence reinforcing the metastatic 
potential of the tumor. It has been found that PTHrP plays a 
key role in cyclin D1 regulation leading to cell proliferation 
in other cell systems. PTHrP coupled with ectopic  receptor 
expression augmented DNA synthesis in MCF-7 breast can-
cer cell line.25 Proliferation of human SV40-immortalized 
breast epithelial cells and colon cancer cells was also trig-
gered by PTHrP. PTHrP enhanced the PC-3 PCa cell adhesion 
to fibronectin, collagen type 1, and laminin.26 Antiapoptotic 
effect of PTHrP was also observed in lung and breast cancer 
cells through intracrine mechanism.27
PTHrP not only facilitates tumor localization and growth 
in the bone, but also is closely associated with tumor-born 
skeletal lesions and complications. It was suggested that 
overexpression of PTHrP provides survival advantages to 
tumor cells in the bone matrix, most probably by stimulating 
osteoclastic destruction. Tumor cells release mediators to 
either stimulate differentiation of hematopoietic stem cells 
into osteoclasts or activate mature osteoclasts or do both.28 It 
was observed that in breast carcinoma, in particular, PTHrP 
produced by the tumor cells is primarily responsible for 
osteolytic bone destruction at the site of tumor metastasis 
to bone. After invading the hard calcified bone matrix, the 
tumor increases the expression of PTHrP together with other 
factors such as IGF-1, IGF-II, FGF1, FGF2, TGFs (TGF-α, 
TGF-β) and platelet-derived growth factors to dramatically 
modify the bone microenvironment and gain growth advan-
tages leading to bone lesion and complications.29 Only a 
small cell population of the primary tumor, endowed with 
specific phenotypic features, has the capacity for successful 
bone metastases. These cells invade the basement membrane, 
evoke angiogenesis, adhere to bony skeleton, and ultimately 
extravasate into its microenvironment to proliferate exponen-
tially, thus instigating macrometastases. A large number of 
factors in the bone tissue, such as interleukins, PTHrP, and 
TGF-β, create a friendly environment for rapid prolifera-
tion of tumor cells. Clinical evidences indicate the strong 
involvement of PTHrP in the pathophysiology of metastases 
to bone as >90% cases of breast carcinoma show predilection 
to bone metastases and are associated with overexpression 
of PTHrP.30 Bone resorption results in elevated local calcium 
concentration and releases TGF-β growth factor, which 
is stored abundantly in the bone microenvironment. High 
calcium level facilitates cancer cell proliferation through 
calcium sensing receptor and also induces PTHrP synthesis 
from the tumor, providing a cyclic feedback maintenance 
system for the cancer cells’ localization and growth in 
bone.31 A large body of studies indicate that the interaction 
of activated osteoclasts and cytokines released by the cancer 
cells results in enhanced bone lysis leading to loss of its 
architectural integrity.
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Prostate cancer bone metastasis
Conclusion and open questions
PCa is not a truly localized disease and to control this 
fact, the recommended treatment is “androgen ablation”, a 
strategy that takes advantage of the tumor’s dependence on 
androgens as a growth factor. The majority of PCa patients 
receiving androgen ablation therapy will ultimately develop 
castration-resistant PCa within 13 years with a median 
survival time of 12 years. Median time to prostate-specific 
antigen progression was recorded to be significantly shorter 
with bone metastases.1
In tumor cell dormancy in PCa, the dormant state con-
fers resistance to conventional chemotherapeutic agents and 
prevents the elimination of disseminated tumor cells from 
the bone using current drug therapies.32 Expansion of limited 
understanding of the molecular mechanisms underpinning 
disseminated prostate tumor cell dormancy is critical for 
the future development of novel drug therapies aimed at the 
prevention of bone metastasis.
Successful therapeutic strategies for the treatment of 
osteolytic MBD include the administration of intravenous 
bisphosphonates or subcutaneous inhibitors of receptor 
activator of RANKL. Inhibitors of SRC and cABL kinases 
and cathepsin K are under clinical investigation as potential 
antiosteolytics. Sclerostin is encoded as a SOST gene prod-
uct that reduces osteoblastic bone formation by inhibiting 
canonical Wnt/β-catenin signaling. It has proved to upregu-
late the expression of RANKL by osteocyte-like cells and 
promotes osteoclastogenesis.12 Similarly, CAPE may prove 
to be a potential intervention for PCa metastasis, since 
preclinical trials verified that it suppresses the migration 
and invasion of PCa cells via activation of non-canonical 
Wnt signaling.
We have emphasized on Wnt signaling pathways due to 
its complex role in tumor-induced osteoblastic activity in 
advanced-stage bone metastasis. Wnts and their downstream 
effectors such as BMP, PTHrP, and OPG are important in 
tumor growth and metastasis leading to osteoblastic phe-
notype transition. PCa is distinct from other cancers in that 
the early stage of bone metastasis is marked by bone lysis, 
while the advanced stage is associated with osteoblastic 
lesions, that is, bone formation. Constitutive activation of 
Wnt signaling pathway contributes toward bone metastasis 
together with its osteoblastic phenotype. Studies have estab-
lished the oncogenic activity of Wnts, and it is found that 
both canonical and non-canonical Wnt signaling pathways 
activate BMP-dependent as well as BMP-independent osteo-
blast differentiation leading to osteoblastic lesions. Thus, 
Wnt is a potential target from the therapeutic development 
standpoint that interferes with PCa bone metastasis. In this 
regard, new agents have been discovered and successively 
tested in preclinical models to mend Wnt signaling.
Applications of these therapeutic strategies could change 
the status of “hormone-refractory PCa” metastatic to bone 
from irremediable to manageable clinical pathosis. This dis-
cussion provides an overview of the main putative molecular 
mechanisms in PCa bone metastasis reported from multiple 
experimental in vitro and in vivo models, and may help to 
discover new therapeutic strategies to control tumor invasion 
and suppress the PCa metastatic bone lesions.
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